Omega Therapeutics, INC

Omega Therapeutics has filed for Chapter 11 bankruptcy and entered into an asset purchase agreement with Pioneering Medicines 08-B, Inc., an affiliate of Flagship Pioneering, Inc., to sell substantially all of its assets.

Omega Therapeutics has filed for Chapter 11 bankruptcy and obtained debtor-in-possession (DIP) financing to continue operations while pursuing a sale of its assets.

Omega Therapeutics has entered a Restructuring Support Agreement (RSA) with Flagship Pioneering affiliates, contemplating a potential sale of assets and a Chapter 11 filing.

Omega Therapeutics reports the resignation of two board members and the appointment of a new director, along with a reclassification of another director to balance board membership.

Omega Therapeutics received a notice of default from Banc of California, who declared the company's loan immediately due and payable, citing concerns over cash runway, financing, solvency, pre-clinical programs, stock price, and corporate governance.

Christian S. Schade resigned from his position as Chair and member of the Board of Directors of Omega Therapeutics, Inc., effective immediately on January 10, 2025.

Omega Therapeutics reported its Q3 2024 financial results, highlighting a strategic prioritization aimed at extending its cash runway into the second quarter of 2025.

Omega Therapeutics' Q2 2024 report highlights a strategic prioritization, resulting in reduced operating expenses and a cash runway into Q1 2025.

Omega Therapeutics announced its first quarter 2024 financial results, highlighting a strategic prioritization to extend its cash runway into the first quarter of 2025.

Omega Therapeutics' 10-K filing highlights its progress in developing programmable epigenomic mRNA medicines, including clinical trial updates and strategic collaborations.

Director Ravi Mehrotra of Omega Therapeutics acquired 50,000 stock options at an exercise price of $0.949 on December 3, 2024.

Omega Therapeutics' Chief Scientific Officer, Jennifer Ann Nelson, has been granted 110,000 stock options with a vesting schedule starting in November 2025.

Omega Therapeutics' CEO, Kaan Certel, was granted 340,000 stock options with a vesting schedule starting in 2025.

Robert L. Rosiello, a director of Omega Therapeutics, Inc., acquired 50,000 stock options on October 2, 2024.

Director Mary Szela acquired 25,000 stock options in Omega Therapeutics, Inc. on June 20, 2024.

Director Rainer J. Boehm reports the acquisition of stock options in Omega Therapeutics, Inc.

Omega Therapeutics, Inc. announces its 2022 Annual Meeting of Stockholders to be held on June 8, 2022, and provides information on how to access proxy materials and vote.

Omega Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, featuring proposals including director elections, auditor ratification, and an amendment to exculpate officers from certain fiduciary duty breaches.

Omega Therapeutics, Inc. has entered into a Restructuring Support Agreement with Flagship Pioneering affiliates, signaling an imminent Chapter 11 bankruptcy filing, a sale of substantially all assets, and securing debtor-in-possession financing.

FMR LLC and its affiliate Abigail P. Johnson have filed an amended Schedule 13G, reporting a complete divestment of their beneficial ownership in Omega Therapeutics Inc., reducing their stake to 0.0%.